Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Positive
AI Analysis
Summary
Angelini Pharma has entered into a definitive agreement to acquire Catalyst Pharmaceuticals for $4.1 billion USD, marking Angelini's entry into the U.S. market and strengthening its position in brain health and rare disease therapeutics.
Outcome Details
Definitive agreement entered for acquisition at $4.1 billion USD ($3.5 billion Euros)
Importance:8/10
Sentiment:
0.70
M&AAcquisitionBrain HealthRare DiseaseMarket Entry
Related Companies
Read the original article
Published by GlobeNewswire Pharma on May 7, 2026 6:14 AM